Register for free
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Neurocrine Biosciences, Inc. - Common Stock (NQ:NBIX)

137.03 +0.29 (+0.21%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Neurocrine Biosciences, Inc. - Common Stock

< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
Benzinga's Top Ratings Upgrades, Downgrades For March 3, 2023
 
Via Benzinga
Sentia Medical Sciences and Neurocrine Biosciences Extend Research Collaboration to Discover Novel CRF Peptides
From Sentia Medical Sciences, Inc.
Via GlobeNewswire
Neurocrine Bio Tops Fourth-Quarter Views As Profit Skyrockets
Neurocrine also topped fourth-quarter revenue expectations on Monday. 
Via Investor's Business Daily
Neurocrine Biosciences Earnings Preview
 
Via Benzinga
Why Voyager Therapeutics Stock Is Sinking This Week
Investors are taking profits on this red-hot stock this week. 
Via The Motley Fool
Earnings Scheduled For February 6, 2023
Companies Reporting Before The Bell • Cummins (NYSE:CMI) is projected to report quarterly earnings at $4.56 per share on revenue of $7.21 billion. 
Via Benzinga
Five Best And Worst Performing Healthcare Stocks In January 2023
After a sub-par performance in 2021, healthcare stocks outperformed the S&P 500 in 2022. As well, 2023 is expected to be another promising year for the sector. Let’s take a look at the five best and... 
Via Talk Markets
Benzinga's Top Ratings Upgrades, Downgrades For February 3, 2023
 
Via Benzinga
Analyst Views Karuna Therapeutics' New Licensing Deal 'As Intriguing'
 
Via Benzinga
Pliant Therapeutics Gaps 34% Higher: More Upside To Come?
Pliant Therapeutics zoomed 34% higher and added to that gain in the next session.This followed good news about clinical trials for a lung-condition treatment. 
Via MarketBeat
7 A-Rated Stocks to Buy for Less Than $25
These seven stocks to buy for less than $25 per share are strong opportunities in today's resilient yet uncertain market. 
Via InvestorPlace
Stock Market Rally Gains Steam As Inflation Cools; Tesla Price Cuts, Big Earnings In Focus: Weekly Review
Sharp Tesla price cuts and some notable earnings were in focus. 
Via Investor's Business Daily
Voyager Therapeutics (VYGR) Stock Gains 18% on Gene Therapy Deal
Voyager Therapeutics' lucrative arrangement with a fellow biotech business is putting VYGR stock traders in a buying mood today. 
Via InvestorPlace
Neurocrine Biosciences, Voyager Therapeutics Collaborate For Neurological-Focused Gene Therapies
 
Via Benzinga
Have A Look At William Blair's Top Biotech Picks For 2023
William Blair & Company's report outlined some key themes and significant trends to monitor while entering 2023, providing its top stock ideas for the upcoming 12-month period. 
Via Benzinga
Dow Jones Giant UnitedHealth Among 5 Resilient Stocks In Sickly Market Rally
UnitedHealth is among medical stocks holding key support. 
Via Investor's Business Daily
Despite Neurocrine's Epilepsy Drug Missing Primary Goal In Pediatric Trial, Analyst Sees Strong Growth
 
Via Benzinga
How to Trade the High-Growth Biotech Sector in the Midst of a Bear Market
Biotech is an exciting and emerging space that’s attracted increasing investor interest in recent years. 
Via Benzinga
Biotech Stocks Embrace The Neuroscience Renaissance With Biogen, Amylyx At The Helm
Neurodegenerative disorders could mean big bucks for some biotechs. 
Via Investor's Business Daily
Stocks That Hit 52-Week Lows On Thursday
  During Thursday's session, 108 stocks hit new 52-week highs. 
Via Benzinga
Heska To $165? Plus BTIG Cuts PT On This Stock By 67%
BTIG cut the price target on Gain Therapeutics, Inc. (NASDAQ: GANX) from $30 to $10. BTIG analyst Thomas Shrader maintained a Buy rating on the stock. Gain Therapeutics shares rose 1.3% to close at... 
Via Benzinga
Is Mid-Cap Neurocrine Biosciences A Buy After Blowout Q3 Report?
Neurocrine Biosciences trended higher with the broad market Thursday, coming within a penny of Tuesday’s high of $125.99. It is forming a bullish channel. 
Via MarketBeat
Looking Into Neurocrine Biosciences's Return On Capital Employed
According to Benzinga Pro, during Q3, Neurocrine Biosciences (NASDAQ:NBIX) earned $68.50 million, a 505.33% increase from the preceding quarter. Neurocrine Biosciences also posted a total of $387.90... 
Via Benzinga
Stock Market Rally Tumbles On Hawkish Fed Chief Powell; Jobs, Earnings Also In Focus: Weekly Review
A mixed jobs report and heavy earnings swung stocks. 
Via Investor's Business Daily
Blazing Hot Neurocrine Biosciences, With 35% Run This Year, Extends Breakout On Quarterly Beat
The company raised its guidance for Ingrezza sales in 2022. 
Via Investor's Business Daily
Neurocrine Biosciences: Q3 Earnings Insights
Neurocrine Biosciences (NASDAQ:NBIX) reported its Q3 earnings results on Tuesday, November 1, 2022 at 07:30 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 11, 2022
Upgrades 
Via Benzinga
Earnings Scheduled For November 1, 2022
Companies Reporting Before The Bell • BP (NYSE:BP) is estimated to report quarterly earnings at $2.07 per share on revenue of $64.76 billion. 
Via Benzinga
3 Top Biotech Stocks Defying the Bear Market
Bear market, shmear market. These biotech stocks are soaring despite the market downturn. 
Via The Motley Fool
Mainz Biomed (MYNZ) nominates two notable leaders in key areas of the diagnostics field to its Board of Directors
Via AB Newswire
< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS